Intellia Therapeutics (NTLA) to Release Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Intellia Therapeutics to post earnings of ($1.26) per share and revenue of $11.39 million for the quarter.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $7.25 on Wednesday. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.18. The firm has a market capitalization of $750.98 million, a P/E ratio of -1.33 and a beta of 2.33. The business’s 50-day simple moving average is $8.23 and its 200-day simple moving average is $11.26.

Wall Street Analyst Weigh In

NTLA has been the subject of several research reports. Barclays decreased their price objective on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Truist Financial decreased their target price on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. The Goldman Sachs Group reissued a “sell” rating and set a $9.00 price target on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, HC Wainwright started coverage on shares of Intellia Therapeutics in a research report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $36.68.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.